HY-0102 Monotherapy in Patients With Locally Advanced/Metastatic Solid Tumours
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a Phase I, first-in-human trial to evaluate the Safety, Tolerability,
Pharmacokinetics and Preliminary Antitumor Activity of HY-0102 administered intravenously
(IV) once every two weeks in adult patients with locally advanced/metastatic malignant solid
tumors.